TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility
Brief Summary: The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of constipation in elderly subjects living in a nursing facility.

Hypothesis:

Prucalopride up to a dose of 4 mg once daily is safe and well tolerated in in elderly subjects living in a nursing facility.


Options:
A: Arm Label: A3309 15 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: A3309 20 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: A3309; Assigned to Arm(s): A3309 15 mg, A3309 20 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 4
C: Arm Label: 72 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 145 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 290 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 579 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: linaclotide acetate; Assigned to Arm(s): 145 ug linaclotide acetate, 290 ug linaclotide acetate, 579 ug linaclotide acetate, 72 ug linaclotide acetate | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness
Brief Summary: The purpose of this study is to determine whether regular oral use of sildenafil citrate can prevent or attenuate high altitude illnesses.


Options:
A: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
C: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness
Brief Summary: The purpose of this study is to determine whether regular oral use of sildenafil citrate can prevent or attenuate high altitude illnesses.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: macitentan (ACT-064992) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: macitentan (ACT-064992) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: macitentan (ACT-064992); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: macitentan (ACT-064992); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Sildenafil plus pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Arm Label: Placebo plus pulmonary rehabilitation; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil plus pulmonary rehabilitation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo plus pulmonary rehabilitation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria.
Brief Summary: To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Levocetirizine; Type: EXPERIMENTAL; Interventions: Drug: Levocetirizine | Intervention Type: DRUG; Name: Levocetirizine; Assigned to Arm(s): Levocetirizine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: desloratadine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: desloratadine | Intervention Type: DRUG; Name: desloratadine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: desloratadine; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Omalizumab | Arm Label: Omalizumab 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Arm Label: Omalizumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Arm Label: Omalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab 150 mg, Omalizumab 300 mg, Omalizumab 75 mg, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Levocetirizine; Type: EXPERIMENTAL; Interventions: Drug: Levocetirizine 1.25 mg | Intervention Type: DRUG; Name: Levocetirizine 1.25 mg; Assigned to Arm(s): Levocetirizine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates
Brief Summary: The purpose of the study is to determine if colonoscopic examination using a colonoscope with a narrow band imaging light is more effective at detecting polyps compared to a colonoscope with standard full spectrum white light.


Options:
A: Arm Label: Narrow band imaging colonoscope; Type: EXPERIMENTAL; Interventions: Device: Narrow band imaging colonoscope | Arm Label: White Light; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Narrow band imaging colonoscope; Assigned to Arm(s): Narrow band imaging colonoscope
B: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Narrow Band Imaging; Assigned to Arm(s): N/A
D: Arm Label: colonoscopy; Type: EXPERIMENTAL; Interventions: Device: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test) | Intervention Type: DEVICE; Name: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test); Assigned to Arm(s): colonoscopy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Patients With COPD (SMOCC) in General Practice
Brief Summary: Background: Smoking cessation is the key element in the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The role of the general practice in assisting these patients with successful quitting smoking was suboptimal. Therefore we evaluated the effectiveness of two smoking cessation programs (counseling and nicotine replacement) for smokers with COPD in routine general practice, one with (CNB) and one without (CN) the combination with bupropion-SR, compared to usual care (UC) and explored the role of COPD symptoms in successful smoking cessation.

Method: RCT with 667 patients with COPD, 68 general practices were randomly allocated. The usual care group (UC) consisted of 148 patients (22 practices), the first intervention group (counseling plus nicotine replacement (CN) of 243 patients (21 practices) and the second intervention group of 276 patients (25 practices. Main outcome measure was (biochemically verified) point prevalence.


Options:
A: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
C: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Patients With COPD (SMOCC) in General Practice
Brief Summary: Background: Smoking cessation is the key element in the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The role of the general practice in assisting these patients with successful quitting smoking was suboptimal. Therefore we evaluated the effectiveness of two smoking cessation programs (counseling and nicotine replacement) for smokers with COPD in routine general practice, one with (CNB) and one without (CN) the combination with bupropion-SR, compared to usual care (UC) and explored the role of COPD symptoms in successful smoking cessation.

Method: RCT with 667 patients with COPD, 68 general practices were randomly allocated. The usual care group (UC) consisted of 148 patients (22 practices), the first intervention group (counseling plus nicotine replacement (CN) of 243 patients (21 practices) and the second intervention group of 276 patients (25 practices. Main outcome measure was (biochemically verified) point prevalence.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
B: Arm Label: Targeted self-management barrier support; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management barrier support | Arm Label: Guided COPD education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic COPD Education | Intervention Type: BEHAVIORAL; Name: Self-management barrier support; Assigned to Arm(s): Targeted self-management barrier support | Intervention Type: BEHAVIORAL; Name: Basic COPD Education; Assigned to Arm(s): Guided COPD education
C: Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Pulmonary rehabilitation | Intervention Type: OTHER; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation
D: Arm Label: Case method education in COPD; Type: EXPERIMENTAL; Interventions: Behavioral: Case method education in COPD | Arm Label: Traditional education in COPD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional education in COPD | Intervention Type: BEHAVIORAL; Name: Case method education in COPD; Assigned to Arm(s): Case method education in COPD | Intervention Type: BEHAVIORAL; Name: Traditional education in COPD; Assigned to Arm(s): Traditional education in COPD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Patients With COPD (SMOCC) in General Practice
Brief Summary: Background: Smoking cessation is the key element in the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The role of the general practice in assisting these patients with successful quitting smoking was suboptimal. Therefore we evaluated the effectiveness of two smoking cessation programs (counseling and nicotine replacement) for smokers with COPD in routine general practice, one with (CNB) and one without (CN) the combination with bupropion-SR, compared to usual care (UC) and explored the role of COPD symptoms in successful smoking cessation.

Method: RCT with 667 patients with COPD, 68 general practices were randomly allocated. The usual care group (UC) consisted of 148 patients (22 practices), the first intervention group (counseling plus nicotine replacement (CN) of 243 patients (21 practices) and the second intervention group of 276 patients (25 practices. Main outcome measure was (biochemically verified) point prevalence.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Self-Management Plan | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD Self-Management Plan; Assigned to Arm(s): Intervention Group
B: Arm Label: Outreach visits; Type: EXPERIMENTAL; Interventions: Behavioral: Outreach visits | Arm Label: Control (late intervention); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Outreach visits; Assigned to Arm(s): Outreach visits
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
D: Arm Label: Pulmonary Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Intervention; Assigned to Arm(s): Pulmonary Rehabilitation Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Patients With COPD (SMOCC) in General Practice
Brief Summary: Background: Smoking cessation is the key element in the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The role of the general practice in assisting these patients with successful quitting smoking was suboptimal. Therefore we evaluated the effectiveness of two smoking cessation programs (counseling and nicotine replacement) for smokers with COPD in routine general practice, one with (CNB) and one without (CN) the combination with bupropion-SR, compared to usual care (UC) and explored the role of COPD symptoms in successful smoking cessation.

Method: RCT with 667 patients with COPD, 68 general practices were randomly allocated. The usual care group (UC) consisted of 148 patients (22 practices), the first intervention group (counseling plus nicotine replacement (CN) of 243 patients (21 practices) and the second intervention group of 276 patients (25 practices. Main outcome measure was (biochemically verified) point prevalence.


Options:
A: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling and spirometry | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: Behavioral: Smoking cessation advice | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling and spirometry; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Brief Advice (SBA) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Structured Brief Advice (SBA); Assigned to Arm(s): 2
C: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Patients With COPD (SMOCC) in General Practice
Brief Summary: Background: Smoking cessation is the key element in the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). The role of the general practice in assisting these patients with successful quitting smoking was suboptimal. Therefore we evaluated the effectiveness of two smoking cessation programs (counseling and nicotine replacement) for smokers with COPD in routine general practice, one with (CNB) and one without (CN) the combination with bupropion-SR, compared to usual care (UC) and explored the role of COPD symptoms in successful smoking cessation.

Method: RCT with 667 patients with COPD, 68 general practices were randomly allocated. The usual care group (UC) consisted of 148 patients (22 practices), the first intervention group (counseling plus nicotine replacement (CN) of 243 patients (21 practices) and the second intervention group of 276 patients (25 practices. Main outcome measure was (biochemically verified) point prevalence.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2

Answer: C